ArticleTranslational cancer research2025
Outcomes of radiotherapy combined with immune checkpoint inhibitors in locally advanced unresectable esophageal squamous cell carcinoma: a retrospective analysis.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The benefit of immune checkpoint inhibitors (ICIs) for esophageal cancer has been investigated and integrated into the treatment strategy. The integration of ICIs with radiotherapy offers significant potential for future applications in patients with locally advanced unresectable esophageal squamous cell carcinoma (ESCC). This study aimed to investigate the outcomes of ICIs combined with radiotherapy. Methods: In this study, we enrolled patients with locally advanced unresectable ESCC who presented to Zhejiang Cancer Hospital between May 2019 and August 2021. The characteristics, survival outcomes, and toxicities of the patients were analyzed. Univariable and multivariable Cox regression analyses were performed to identify the factors associated with survival. Results: A total of 92 patients with locally advanced unresectable ESCC were enrolled. The median follow-up period was 18.2 months. The rates of 24-month progression-free survival (PFS) and overall survival (OS) in the entire group were 33.7% and 39.1%, respectively. Radiotherapy showed better survival outcomes when concurrently administered with ICIs or chemotherapy than when used as a standalone treatment. High-grade (≥ grade 3) adverse events occurred in 48.9% of our patients. One patient died of severe pneumonia after receiving the combination therapy; this patient had a previous history of severe interstitial pneumonia. Conclusions: Radiotherapy combined with ICIs is a promising method to treat patients with locally advanced unresectable ESCC. Future prospective randomized clinical trials should evaluate combination strategies for such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.